Compare BTT & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTT | TNDM |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2013 |
| Metric | BTT | TNDM |
|---|---|---|
| Price | $22.79 | $23.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 18 |
| Target Price | N/A | ★ $27.89 |
| AVG Volume (30 Days) | 109.4K | ★ 2.7M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | N/A | $12.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $20.20 | $10.00 |
| 52 Week High | $23.08 | $29.65 |
| Indicator | BTT | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 47.46 | 58.27 |
| Support Level | $22.48 | $19.66 |
| Resistance Level | $22.90 | $24.23 |
| Average True Range (ATR) | 0.14 | 1.17 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 44.21 | 66.84 |
Blackrock Municipal 2030 Target Term Trust is a United States-based closed-end management investment company. The investment objective of the company is to provide current income exempt from regular federal income tax and to return $25.00 per common share to holders of common shares. The trust seeks to achieve its investment objectives by investing a majority of its assets in municipal bonds exempt from U.S. federal income taxes.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.